Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.
The conversation discusses hair loss treatments, specifically the use of dutasteride, finasteride, and the potential of mesotherapy. The user experiences hair loss despite low DHT levels and considers localized dutasteride treatment, while others suggest consulting a dermatologist and exploring other causes like malabsorption.
The conversation discusses using hormones like pregnenolone and tongkat ali to counteract sexual side effects from hair loss medications such as finasteride, dutasteride, ketoconazole, and minoxidil. The user stopped the other medications but continues using minoxidil while seeking advice on maintaining libido.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.
A user on Finasteride for over a year is asking if taking Glycine 1000 mg at night along with morning collagen peptides will increase DHT and cause hair loss. They are concerned about the potential impact on their hair loss treatment.
A 22-year-old with advanced diffuse thinning is considering oral dutasteride after stopping finasteride due to side effects like brain fog and testicular pain. They are also contemplating a hair transplant combined with oral dutasteride and topical finasteride, noting a thick donor area.
The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.
DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Taking dutasteride with a meal containing fat may improve absorption, but consistency in routine is more important than timing. Minor variations in absorption won't significantly affect efficacy due to dutasteride's long half-life.
People are discussing the effectiveness of Breezula for hair loss maintenance. Some individuals are using Breezula alone, avoiding finasteride, and one plans to use Breezula after a hair transplant.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.
Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.
Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.
The user experienced bladder and prostate discomfort after taking finasteride and stopped the medication, but symptoms returned upon resuming at a lower dose. The doctor suggested trying dutasteride as an alternative.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.